Evidence map›Paper›PMID 27411022›Full record

ArticleBritish journal of haematology2016

Multiple myeloma: patient outcomes in real-world practice.

Kwee Yong, Michel Delforge, Christoph Driessen, Leah Fink, Alain Flinois, Sebastian Gonzalez-McQuire, Reza Safaei, Lionel Karlin, Maria-Victoria Mateos, Marc S Raab and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05199311 (A Phase I/II Study of Carfilzomib, Iberdomide), which is not on this map. Cited by 177 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05199311 phase1 / phase2suspendednot on this mapstarted 2022, after this paper: background citation

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

TypeinterventionalSponsorHackensack Meridian HealthRan2022 to 2027Enrolled66ConditionsMultiple MyelomaArmsCarfilzomib, Iberdomide, Oral Dexamethasone
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Teclistamab in Relapsed or Refractory Multiple Myeloma.The New England journal of medicine · 2022
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kwee YongDepartment of Haematology, University College London, London, UK. kwee.yong@ucl.ac.uk.
Michel DelforgeDepartment of Haematology, UZ Leuven, Leuven, Belgium.
Christoph DriessenDepartment of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.
Leah FinkKantar Health, Montrouge, France.
Alain FlinoisKantar Health, Montrouge, France.
Sebastian Gonzalez-McQuireGlobal Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
Reza SafaeiGlobal Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
Lionel KarlinCentre Hospitalier Lyon-Sud, Lyon, France.
Maria-Victoria MateosDepartment of Hematology, University Hospital of Salamanca, Salamanca, Spain.
Marc S RaabDepartment of Internal Medicine, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4181-6922
Paul SchoenValue Access & Policy, Amgen (Europe) GmbH, Zug, Switzerland.
Michele Cavo'Seràgnoli' Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We investigated patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK. In total, 435 physicians retrospectively reviewed 4997 patient charts. Profiles of patients diagnosed with multiple myeloma during the last 12 months were similar across countries; bone pain was the most common presentation. Median duration of first-line therapy was 6 months, followed by a median treatment-free interval of 10 months; both these decreased with increasing lines of therapy, as did time to progression. Depth of response, as assessed by the treating physician, also decreased with each additional line of therapy: 74% of patients achieved at least a very good partial response at first line, compared with only 11% at fifth line. Deeper responses were associated with longer time to progression, although these were physician-judged. Toxicities and co-morbidities increased with later treatment lines, and were more likely to have led to discontinuation of treatment. These real-world data provide an insight into patient outcomes and treatment decisions being made in clinical practice.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsComorbidityCross-Sectional StudiesDisease ManagementDisease ProgressionEuropeFemaleHealth Care SurveysHumansMaleMiddle AgedMultiple MyelomaOutcome Assessment, Health CarePhenotypedepth of responseduration of therapymultiple myelomapatient chart reviewreal-world practice

Identifiers

PMID27411022
PMCPMC5096152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.